Vivalavita Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 23-12-2024
- Paid Up Capital ₹ 0.10 M
as on 23-12-2024
- Company Age 12 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 2.10 Cr
as on 23-12-2024
- Revenue 182.52%
(FY 2023)
- Profit 181.47%
(FY 2023)
- Ebitda 30.21%
(FY 2023)
- Net Worth 7.23%
(FY 2023)
- Total Assets 47.11%
(FY 2023)
About Vivalavita Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company has closed loans amounting to ₹2.10 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Ajay Melwani and Ayush Melwani serve as directors at the Company.
- CIN/LLPIN
U52311MH2012PTC227367
- Company No.
227367
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 Feb 2012
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Vivalavita Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ajay Melwani  | Director | 23-Feb-2012 | Current |
| Ayush Melwani | Director | 07-Sep-2018 | Current |
Financial Performance of Vivalavita Pharmaceuticals.
Vivalavita Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 182.52% increase. The company also saw a substantial improvement in profitability, with a 181.47% increase in profit. The company's net worth moved up by a moderate rise of 7.23%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Vivalavita Pharmaceuticals?
In 2020, Vivalavita Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Sirius Pharmaceuticals Private LimitedActive 33 years 2 monthsAjay Melwani and Ayush Melwani are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Icici Bank Limited Creation Date: 22 Mar 2012 | ₹2.10 Cr | Satisfied |
How Many Employees Work at Vivalavita Pharmaceuticals?
Unlock and access historical data on people associated with Vivalavita Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Vivalavita Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Vivalavita Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
